Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy

被引：22
|
作者：
Huang, Zhao-Hui [1 ,2 ]
Hua, Dong [1 ]
Li, Li-Hua [1 ]
Zhu, Jing-De [2 ]
机构：
[1] Suzhou Univ, Affiliated Hosp 4, Wuxi Oncol Inst, Wuxi 214062, Jiangsu Prov, Peoples R China
[2] Fudan Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Coll Med, Shanghai 200032, Peoples R China
来源：
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2008年 / 134卷 / 10期
关键词：
gastric cancer; chemotherapy; polymorphism; P53; protein; 5-fluorouracil; apoptosis;
D O I：
10.1007/s00432-008-0380-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective The polymorphism of p53 codon 72 (Arg72Pro) has been suggested to play an important role in many cancers and may influence the response to chemotherapy. Our aim was to investigate the association of p53 Arg72Pro polymorphism with the clinical outcome of gastric cancer patients treated with 5-FU-based adjuvant chemotherapy. Methods The p53 codon 72 genotype was determined in blood samples from 110 Chinese patients with gastric cancer treated with 5-fluorouracil (5-FU)-based adjuvant chemotherapy, using polymerase chain reaction-ligation detection reaction (PCR-LDR) method. Results Kaplan-Meier survival analysis showed that gastric cancer patients with Pro/Pro genotype had shorter relapse-free survival (chi(2) = 10.632, P = 0.005) and overall survival (chi(2) = 7.104, P = 0.029) than patients with other genotypes. Cox multivariate analysis showed that Pro/Pro genotype was associated with statistically significant reduced relapse-free survival (adjusted OR = 3.049, 95% CI: 1.363-6.819, P = 0.007) and overall survival (adjusted OR = 2.581, 95% CI: 1.052-6.330, P = 0.038). Conclusion These results suggested that p53 codon 72 polymorphism appears to be an independent prognostic factor in gastric cancer patients treated with 5-FU-based adjuvant chemotherapy.
引用
收藏
页码：1129 / 1134
页数：6
相关论文
共 50 条
  • [21] Germline polymorphism of p53 codon 72 in gynecological cancer
    Ueda, M
    Terai, Y
    Kanda, K
    Kanemura, M
    Takehara, M
    Yamaguchi, H
    Nishiyama, K
    Yasuda, M
    Ueki, M
    GYNECOLOGIC ONCOLOGY, 2006, 100 (01) : 173 - 178
  • [22] p53 codon 72 polymorphism and urothelial cancer risk
    Kuroda, Y
    Tsukino, H
    Nakao, H
    Imai, H
    Katoh, T
    CANCER LETTERS, 2003, 189 (01) : 77 - 83
  • [23] p53 codon 72 polymorphism and risk of cervical cancer
    Ojeda, JM
    Ampuero, S
    Rojas, P
    Prado, R
    Allende, JE
    Barton, SA
    Chakraborty, R
    Rothhammer, F
    BIOLOGICAL RESEARCH, 2003, 36 (02) : 279 - 283
  • [24] The p53 codon 72 polymorphism and lung cancer risk
    Fan, R
    Wu, MT
    Miller, D
    Wain, JC
    Kelsey, KT
    Wiencke, JK
    Christiani, DC
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2000, 9 (10) : 1037 - 1042
  • [25] The p53 codon 72 polymorphism and association to prostate cancer in Iranian patients
    Doosti, Abbas
    Dehkordi, Payam Ghasemi
    AFRICAN JOURNAL OF BIOTECHNOLOGY, 2011, 10 (60): : 12821 - 12825
  • [26] A p53 codon 72 polymorphism associated with breast cancer in Iranian patients
    Doosti, Abbas
    Dehkordi, Payam Ghasemi
    Davoudi, Noushin
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 5 (10): : 1278 - 1281
  • [27] Polymorphism of the p53 gene within the codon 72 in lung cancer patients
    Biros, E
    Kalina, I
    Biros, I
    Kohüt, A
    Bogyiová, E
    Salagovic, J
    Stubña, J
    NEOPLASMA, 2001, 48 (05) : 407 - 411
  • [28] The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients
    Cao, Z.
    Song, J. H.
    Park, Y. K.
    Maeng, E. J.
    Nam, S. W.
    Lee, J. Y.
    Park, W. S.
    NEOPLASMA, 2009, 56 (02) : 114 - 118
  • [29] THE ASSOCIATION OF P53 CODON 72 POLYMORPHISM WITH THYROID CANCER IN TURKISH PATIENTS
    Aral, Cenk
    Caglayan, Sinan
    Ozisik, Gokhan
    Massoumilary, Sirin
    Sonmez, Ozgur
    Akkiprik, Mustafa
    Baloglu, Huseyin
    Ozata, Metin
    Ozer, Ayse
    MARMARA MEDICAL JOURNAL, 2007, 20 (01): : 1 - 5
  • [30] Association of p53 codon 72 polymorphism with resistance to adjuvant therapy in primary breast cancer
    Toyama, T.
    Zhang, Z.
    Hamguchi, M.
    Kondo, N.
    Iwase, H.
    Iwata, H.
    Takahashi, S.
    Yamashita, H.
    Fujii, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345